Abstract
The present invention features imidazolidinone compounds and pharmaceutical compositions of imidazolidinone compounds. The compounds of the invention are utilized in methods of treating a deubiquitination-related disorder in a subject and inhibiting p97-associated deubiquitination.
Claims
-
A method of inhibiting p97 associated deubiquitination and/or inducing ER stress in a subject in need thereof, comprising administering to said subject, an effective amount of a compound of the following Formula (II), or pharmaceutically acceptable salt, solvate or hydrate thereof:
wherein
Q is O, S, or NRA;
R1 is selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted haloalkyl, optionally substituted alkoxy, optionally substituted cycloalkoxy, optionally substituted (cycloalkyl)alkoxy, and optionally substituted heterocycloalkyl;
R2 is selected from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted haloalkyl, optionally substituted alkoxy, optionally substituted cycloalkoxy, optionally substituted (cycloalkyl)alkoxy, and optionally substituted heterocycloalkyl;
Z is an optionally substituted aryl or an optionally substituted heteroaryl; and
n is 0-3.
- A method of claim 1, wherein the subject is suffering from leukemia, multiple myeloma or lymphoma.
- The method of claim 2 additionally comprising administering a proteasome inhibitor to the subject.
- The method of claim 3, wherein the proteasome inhibitor is BORTEZOMIB.
-
A method for treating for leukemia, lymphoma, or multiple myeloma in a subject, the method comprising administering to said subject an effective amount of a compound of formula II:
wherein
Q is O, S, or NRA;
R1 is selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted haloalkyl, optionally substituted alkoxy, optionally substituted cycloalkoxy, optionally substituted (cycloalkyl)alkoxy, and optionally substituted heterocycloalkyl;
R2 is selected from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted haloalkyl, optionally substituted alkoxy, optionally substituted cycloalkoxy, optionally substituted (cycloalkyl)alkoxy, and optionally substituted heterocycloalkyl;
wherein X is O, S, or NRB;
Z is an optionally substituted aryl or an optionally substituted heteroaryl;
and
n is 0-3.
- The method of claim 5, wherein the compound of formula II is:
- The method of claim 5, further comprising an additional therapeutic agent, wherein the additional therapeutic agent is an antineoplastic agent selected from wherein the additional therapeutic agent is an antineoplastic agent selected from an alkylating agent, a folate antagonist, a purine antagonist, a pyrimidine antagonist, a taxane, a topoisomerase, or a therapeutic antibody directed against CD20 or VEGF, or a combination of any of the foregoing.
-
A method of treating a treating a subject suffering from a retroviral infection, comprising administering a compound of the following Formula (II), or pharmaceutically acceptable salt, solvate or hydrate thereof to the subject:
wherein
Q is O, S, or NRA;
R1 is selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted haloalkyl, optionally substituted alkoxy, optionally substituted cycloalkoxy, optionally substituted (cycloalkyl)alkoxy, and optionally substituted heterocycloalkyl;
R2 is selected from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted haloalkyl, optionally substituted alkoxy, optionally substituted cycloalkoxy, optionally substituted (cycloalkyl)alkoxy, and optionally substituted heterocycloalkyl;
Z is an optionally substituted aryl or an optionally substituted heteroaryl; and
n is 0-3.
- The method of claim 2, wherein the subject is resistant to treatment with a proteasome inhibitor.
- The method of claim 2, wherein the subject is resistant to treatment with BORTEZOMIB.
- The method of claim 5, wherein the subject is resistant to treatment with a proteasome inhibitor.
- The method of claim 5, wherein the subject is resistant to treatment with BORTEZOMIB.
- The method of claim 5, further comprising administering an additional therapeutic agent to the subject, wherein the additional therapeutic agent is an antineoplastic agent selected from an alkylating agent, a folate antagonist, a purine antagonist, a pyrimidine antagonist, a taxane, a topoisomerase, or a therapeutic antibody directed against CD20 or VEGF, or a combination of any of the foregoing.
- The method of claim 7, wherein the additional therapeutic agent is an anticancer compound, chosen from mechloroethamine, chlorambucil, cyclophosamide, melphalan, ifosfamide, methotrexate, 6-mercaptopurine, 5-fluorouracil, rituximab, bevacizumab, or a combination of any of the foregoing.
- The method of claim 5, wherein the step of administering the compound comprises administering the compound orally, topically, parentally, intravenously or intramuscularly.
- The method of claim 8, wherein the compound is
- The method of claim 5 additionally comprising administering a proteasome inhibitor to the subject.
- The method of claim 17, wherein the proteasome inhibitor is BORTEZOMIB.
Owners (US)
Applicants
-
Trenkle William
Explore more patents:
-
Wiestner Adrian
Explore more patents:
-
Wang Qiuyan
Explore more patents:
-
Ye Yihong
Explore more patents:
-
Mora-jensen Helena
Explore more patents:
-
Us Health
Explore more patents:
Inventors
-
Trenkle William
Explore more patents:
-
Wiestner Adrian
Explore more patents:
-
Wang Qiuyan
Explore more patents:
-
Ye Yihong
Explore more patents:
-
Mora-jensen Helena
Explore more patents:
CPC Classifications
-
A61K31/4178
Explore more patents:
-
A61K31/4166
Explore more patents:
IPC Classifications
-
A61K31/4166
Explore more patents:
-
C07D233/32
Explore more patents:
Download PDF
Document Preview
Document History
- Publication: Jan 28, 2014
-
Application:
Jul 18, 2008
US 66936108 A
-
Priority:
Jul 18, 2008
US 66936108 A
-
Priority:
Jul 18, 2008
US 2008/0008797 W
-
Priority:
Jul 18, 2007
US 96120207 P